Levels of cefazolin were determined in plasma, urine, bile, and cerebrospinal fluid in humans after a bolus intravenous injection and during a controlled, continuous intravenous infusion. All the patients were studied in a steady-state and crossover fashion. In plasma, the mean peak level after bolus injection (1.5 g) studied in 12 patients was 206.5 ug/ml; during continuous infusion (6 g daily), the mean level remained stable at 52.6 ug/ml. With bolus injection and continuous infusion, respectively, 89.7 and 86.3% of the administered dose of cefazolin were excreted in the urine of nine patients over the 6-h period considered. The levels of cefazolin in common bile duct bile were studied in six cholecystectomized patients. In bile collected during the two 3-h periods of the experiment, the mean concentration of the drug in the bile after bolus injection was 66.9 and 22.0 ,ug/ml, respectively; during continuous infusion, the corresponding biliary levels were 50.7 and 51.3 ,Ag/ml, respectively. In four neurosurgical patients with an intraventricular catheter, neither bolus injection nor continuous infusion resulted in a demonstrable concentration of cefazolin in the cerebrospinal fluid. The continuous intravenous administration of cefazolin might have some advantage over the intravenous bolus intermittent injections. In plasma, the area under the curve is greater with continuous infusion than with bolus injection. In bile, the levels of cefazolin are more sustained with continuous infusion than with bolus injection. This approach to intravenous administration of cefazolin deserves more pharmacological and clinical trials.
To rapidly achieve an optimal concentration of antibiotics in infected sites, large doses of these drugs are frequently administered by the intravenous route. The mode of administration is either the intravenous bolus injection, which provides "peak" and "valley" blood levels, or continuous intravenous infusion, which produces sustained but relatively low concentrations of antibiotics in the blood. Whether one of these techniques of injection should be preferred in order to obtain optimal clinical results is still a matter of controversy.
This investigation was carried out to determine the levels of cefazolin, a relatively new cephalosporin, in various body fluids (plasma, urine, bile, and cerebrospinal fluid [CSF] ) after a bolus intravenous injection and during a continuous intravenous perfusion.
(This paper was presented at the 9th International Congress of Chemotherapy, London, 1975.) MATERIALS AND METHODS The patients, with the exception of those in whom the biliary concentration of cefazolin was studied, were hospitalized in a neurosurgical unit at the Institut Jules Bordet. All had a normal renal function as determined by the creatinine clearance. The daily dose of cefazolin was 6 g. For intermittent administration, 1.5 g (dissolved in 9 ml of 5% dextrose in water) was injected over a 3-min period four times during a 24-h period. In the other experiment, the same amount of cefazolin (6 g) was dissolved in 1,000 ml of 5% dextrose in water and was given as a continuous intravenous infusion using an automated infusion device (Automated Infusion Unit, Decca, London) to strictly control the rate of administration. All the patients studied here received cefazolin by the two techniques of administration on 2 consecutive days.
The samples of the various fluids to be studied were obtained between h 18 and 24 of each experiment, a period that we have considered to represent a steady state. Samples of heparinized blood were obtained at various intervals of time after the bolus injection: 2 min after the end of the injection (thus, 5 min after its onset), and 10 by spontaneous voiding at the end of each 3-h period. These patients had been cholecystectomized for cholelithiasis or a nonfimctioning gall bladder between 5 and 14 days prior to the study. Samples of common bile duct bile were obtained through a Ttube over two 3-h periods.
To study the penetration of cefazolin in the CSF, four patients with no meningeal inflammation who were undergoing a monitoring of their intracranial pressure through an intraventricular catheter were investigated. The catheter allowed the collection of CSF simultaneously to the collection of blood samples.
All samples of plasma, urine, bile, and CSF were stored at -20°C until assayed. The assay of cefazolin in these various fluids was performed as described by Bennett and co-workers (3), using Bacillus subtilis (Subtilis spore suspension, Difco, Detroit, Mich.) as the test organism. Each assay was made in quadruplicate. To dilute the clinical fluid to be assayed and to prepare the reference curves, we used human plasma for plasma assays and human common bile duct bile (without any spontaneous antibacterial activity) for bile assays; for urine and CSF, phosphate buffer was employed. RESULTS Levels in plasma. After the bolus injection, the mean peak plasma level in 12 patients was 206.5 ± 10.9 ug/ml (mean ± standard error of the mean); after 3 and 6 h, the mean plasma levels were 29.1 ± 5.2 and 13.5 ± 3.3 ug/ml, respectively, as shown in Fig. 1 . During the continuous infusion, the mean plasma level remained stable at 52.6 ± 6.5 ug/ml. Based on these data, the area under the curve associated with the continuous infusion was greater by 24.2% than that associated with the bolus injection.
Levels in urine. The urinary excretion of cefazolin was studied in nine patients. As indicated in Fig. 2 , the bolus injection resulted, during the first 3 h after the injection, in a mean concentration of cefazolin of 7,320 ± 1,498 gg/ml and, over this period of time, 1,034 ± 95 mg was excreted. In the urine obtained during the next 3-h period, the mean concentration of cefazolin was 2,348 + 528 gg/ml, and 311.2 ± 58 mg was excreted. During the continuous infusion the corresponding urinary levels of cefazolin were 5,099 + 945 and 5,370 + 830 ,ug/ml, respectively; the amounts of cefazolin excreted were 661.3 + 38 and 634 + 36 mg, respectively, indicating that during the continuous infusion the rate of the urinary excretion of cefazolin was constant.
With the bolus injection and the continuous infusion, respectively, 89.7 and 86.3% of the administered doses of cefazolin were excreted in the urine over the 6-h period considered.
Levels in common bile duct bile. The levels of cefazolin in common bile duct bile were stud- were found in the bile; patient 4 and patient 5 presented signs of biliary tract obstruction, but patient 6 had no such signs. In patients 1 and 2 only very low biliary cefazolin levels were observed; patient 1 had a slight cholostasis, but patient 2 had normal liver function. Levels in CSF. In four patients with an intraventricular catheter, neither the bolus injection nor the continuous infusion of cefazolin resulted in a demonstrable concentration of the antibiotic in ventricular CSF. DISCUSSION The plasma levels of cefazolin obtained here with the intravenous bolus injection are comparable to those obtained by other investigators (5, 8, 16) . The shape of the curve of the plasma levels after the bolus injection is also similar to that observed by others (9, 20 (5, 8) .
In the bile from the common bile duct, the concentration of cefazolin in our patients appeared to be adequate after intermittent and during continuous intravenous administration.
At the dosage used in this study, the biliary levels of cefazolin were adequate against most clinical pathogens. Other authors stressed the good biliary levels of this cephalosporin (4, 11, 15, 17) : the concentrations of cefazolin in the common bile duct bile were usually found to be equal to or higher than the blood level (4, 15, 17) . However, for cefazolin, as for other antibiotics, the biliary concentration is variable from patient to patient, especially if obstruction is present; in this latter condition, the concentrations of antibiotic in the bile are usually extremely low. The biliary levels found in our patients were variable; however, the relationship between cholestasis and the levels of cefazolin in the common bile duct bile did not appear clearly.
We could not find any demonstrable cefazolin in the CSF of four patients without meningeal inflammation. This very poor diffusion of cefazolin through the blood-brain barrier has already been observed by other investigators (1; L. H. Baker, D. R. Hinthorn, D. A. Romig, and C. Liu, Abstr. Clin. Res. XXII:613A, 1974); thus, cefazolin should not be used to treat bacterial meningitis (12) .
The basic problem of the respective effectiveness of intermittent or continuous administration of antibiotics has not yet stimulated many experimental and clinical investigations, and this question is still unsolved. Eagle et al. (6) noted that the total time during which penicillin has to be provided at effective levels is largely independent of the method of administration, provided the interval between successive injections would be short enough as not to allow the multiplication of the surviving bacteria. However, in the experiments of Eagle et al., it was not absolutely necessary to continuously maintain effective levels of penicillin to achieve cure. However, these studies suggested that the most effective form of treatment is the one that provides antibiotics continuously, in excess of the effective levels, so both the drug and the defenses of the host are continuously operative. On the other hand, Schmidt and Walley (19) , using an experimental model of pneumonia in rats, concluded that relatively long intervals between successive administrations of penicillin were more effective than shorter ones. Similarly, in an experimental wound infection model, Ehrlich and co-workers (7) have found that the concentration of cephaloridine in the wound was greater with a bolus injection than with a continuous infusion. In a recent study, Barza and co-workers (2) demonstrated that the accumulation of penicillins and cephalosporins in experimental fibrin clots was greater with repetitive bolus injections than with continuous infusions. These findings appear to be explained by the higher peak concentration in the serum after the bolus injection and by the longer half-life of the antibiotic in the fibrin clots than in the serum. Thus, these observations suggest that an intermittent antibiotic therapy might be more effective than a continuous one.
The major aim of this study was to compare the levels of cefazolin in various sites after direct intravenous injection and during continuous infusion. By comparing the areas under the curves, plasma bioavailability of cefazolin appeared to be greater with continuous infusion than with intermittent injection. In addition, the concentration of cefazolin in common bile duct bile could be maintained at an adequate level with the continuous infusion only.
We also tried to compare the consequences of the two modes of intravenous administration on the CSF cefazolin levels; unfortunately, the very poor penetration of cefazolin through the normal meninges made this comparison impossible. However, experimental data in dogs suggest that the continuous infusion of antibiotics might be more effective in achieving adequate CSF levels than successive bolus injections (14) .
We have attempted to study the penetration of cefazolin within the bronchial secretions: the levels of cefazolin in the bronchial purulent secretions of seven tracheotomized patients seemed to be very low. However, we found it difficult to assay accurately cefazolin in bronchial secretions, owing to a slight spontaneous antimicrobial activity of most specimens. Pennington and Reynolds (13) observed, with gentamicin in dogs, that the penetration into the bronchial fluid was relatively poor. In addition, a rapid intravenous injection of gentamicin produced a high but transient level in the bronchial secretions, but, on the other hand, intramuscular inection resulted in lower levels that were more sustained.
The basic question that we raise in the present study remains largely unsolved since the penetration of cefazolin through the two biological membranes. that we planned to study, the meninges and the bronchial wall, was very poor. Nevertheless, we believe that the optimal way to administer antibiotics deserves further pharmacological and clinical studies.
